RVVC market Mycovia has an FDA approved therapy, VIVJOA, targeting recurrent vulvovaginal candidiasis (RVVC), indicating a direct sales opportunity with obstetrics/gynecology and infectious disease channels, as well as potential expansion with payer pilots and clinic adoption programs.

Global licensing A China licensing agreement with Jiangsu Hengrui Pharmaceuticals suggests a pathway for regional partnerships and co-development opportunities in East Asia; explore similar partnerships in other high-need markets to accelerate reach and share risk.

Oral fungal inhibitors The company flags a pipeline focusing on oral fungal inhibitors and multi-drug resistant pathogens, presenting a potential upstream sales opportunity for clinical research collaborations, diagnostic co-development, and early access programs with hospitals treating resistant infections.

Recent launches VIVJOA launched in 2022 with ongoing availability and promotion since, indicating readiness for market expansion activities, payer negotiations, and physician education campaigns to grow utilization and reimbursement coverage.

Strategic partnerships Past collaborations, including with Gedeon Richter, illustrate a receptiveness to co-development and manufacturing partnerships; approach potential partners for regional manufacturing, co-promotion, or tie-up deals to scale commercialization.